Ghent University Academic Bibliography

Advanced

Ex-ante evaluation of biotechnology innovations : the case of folate biofortified rice in China

Hans De Steur UGent, Dieter Blancquaert, Xavier Gellynck UGent, Willy Lambert and Dominique Van Der Straeten UGent (2012) CURRENT PHARMACEUTICAL BIOTECHNOLOGY. 13(15). p.2751-2760
abstract
In order to valorize novel biotechnology innovations, there is a need to evaluate ex-ante their market potential. A case in point is biofortification, i.e. the enhancement of the micronutrient content of staple crops through conventional or genetic breeding techniques. In a recent article in Nature Biotechnology, for example, De Steur et al. (2010) demonstrated the large potential consumer health benefits of folate biofortified rice as a means to reduce folate deficiency and Neural-Tube Defects. By focusing on a Chinese high-risk region of Neural-Tube Defects, the current study defines the potential cost-effectiveness of this genetically modified crop where the need to improve folate intake levels is highest. Building on the Disability-Adjusted Life Years (DALY) approach, both the potential health impacts and costs of its implementation are measured and benchmarked against similar innovations. The results show that this transgenic crop could be a highly cost-effective product innovation (US$ 120.34 -US$ 40.1 per DALY saved) to alleviate the large health burden of folate deficiency and reduce the prevalence of neural-tube birth defects. When compared with other biofortified crops and target regions, folate biofortified rice in China has a relatively high health impact and moderate cost-effectiveness. This research further supports the need for, and importance of ex-ante evaluation studies in order to adequately market and, thus, valorize biotechnology innovations. Although the cost-effectiveness analysis enables to illustrate the market potential of innovative agricultural biotechnology research, further research is required to address policy issues on transgenic biofortification, such as biosafety regulatory requirements.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
SHANXI PROVINCE, HIGH-RISK REGION, FOLIC-ACID SUPPLEMENTATION, NEURAL-TUBE DEFECTS, transgenic biofortification, genetic modification, folate biofortified rice, Agricultural biotechnology, China, ex-ante evaluation, cost-effectiveness, HIGH-PREVALENCE, COST-EFFECTIVENESS, NORTHERN CHINA, GOLDEN RICE, POTENTIAL IMPACT, HEALTH-BENEFITS
journal title
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Curr. Pharm. Biotechnol.
volume
13
issue
15
pages
2751 - 2760
Web of Science type
Review
Web of Science id
000313045400008
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
2.69 (2012)
JCR rank
97/259 (2012)
JCR quartile
2 (2012)
ISSN
1389-2010
DOI
10.2174/138920112804724873
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
3140537
handle
http://hdl.handle.net/1854/LU-3140537
date created
2013-02-22 15:27:49
date last changed
2017-02-22 12:39:37
@article{3140537,
  abstract     = {In order to valorize novel biotechnology innovations, there is a need to evaluate ex-ante their market potential. A case in point is biofortification, i.e. the enhancement of the micronutrient content of staple crops through conventional or genetic breeding techniques. In a recent article in Nature Biotechnology, for example, De Steur et al. (2010) demonstrated the large potential consumer health benefits of folate biofortified rice as a means to reduce folate deficiency and Neural-Tube Defects. By focusing on a Chinese high-risk region of Neural-Tube Defects, the current study defines the potential cost-effectiveness of this genetically modified crop where the need to improve folate intake levels is highest. Building on the Disability-Adjusted Life Years (DALY) approach, both the potential health impacts and costs of its implementation are measured and benchmarked against similar innovations. The results show that this transgenic crop could be a highly cost-effective product innovation (US\$ 120.34 -US\$ 40.1 per DALY saved) to alleviate the large health burden of folate deficiency and reduce the prevalence of neural-tube birth defects. When compared with other biofortified crops and target regions, folate biofortified rice in China has a relatively high health impact and moderate cost-effectiveness. This research further supports the need for, and importance of ex-ante evaluation studies in order to adequately market and, thus, valorize biotechnology innovations. Although the cost-effectiveness analysis enables to illustrate the market potential of innovative agricultural biotechnology research, further research is required to address policy issues on transgenic biofortification, such as biosafety regulatory requirements.},
  author       = {De Steur, Hans and Blancquaert, Dieter and Gellynck, Xavier and Lambert, Willy and Van Der Straeten, Dominique},
  issn         = {1389-2010},
  journal      = {CURRENT PHARMACEUTICAL BIOTECHNOLOGY},
  keyword      = {SHANXI PROVINCE,HIGH-RISK REGION,FOLIC-ACID SUPPLEMENTATION,NEURAL-TUBE DEFECTS,transgenic biofortification,genetic modification,folate biofortified rice,Agricultural biotechnology,China,ex-ante evaluation,cost-effectiveness,HIGH-PREVALENCE,COST-EFFECTIVENESS,NORTHERN CHINA,GOLDEN RICE,POTENTIAL IMPACT,HEALTH-BENEFITS},
  language     = {eng},
  number       = {15},
  pages        = {2751--2760},
  title        = {Ex-ante evaluation of biotechnology innovations : the case of folate biofortified rice in China},
  url          = {http://dx.doi.org/10.2174/138920112804724873},
  volume       = {13},
  year         = {2012},
}

Chicago
De Steur, Hans, Dieter Blancquaert, Xavier Gellynck, Willy Lambert, and Dominique Van Der Straeten. 2012. “Ex-ante Evaluation of Biotechnology Innovations : the Case of Folate Biofortified Rice in China.” Current Pharmaceutical Biotechnology 13 (15): 2751–2760.
APA
De Steur, Hans, Blancquaert, D., Gellynck, X., Lambert, W., & Van Der Straeten, D. (2012). Ex-ante evaluation of biotechnology innovations : the case of folate biofortified rice in China. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 13(15), 2751–2760.
Vancouver
1.
De Steur H, Blancquaert D, Gellynck X, Lambert W, Van Der Straeten D. Ex-ante evaluation of biotechnology innovations : the case of folate biofortified rice in China. CURRENT PHARMACEUTICAL BIOTECHNOLOGY. 2012;13(15):2751–60.
MLA
De Steur, Hans, Dieter Blancquaert, Xavier Gellynck, et al. “Ex-ante Evaluation of Biotechnology Innovations : the Case of Folate Biofortified Rice in China.” CURRENT PHARMACEUTICAL BIOTECHNOLOGY 13.15 (2012): 2751–2760. Print.